CN115998779B - 一种海蒿子多酚提取物及其制备方法和应用 - Google Patents
一种海蒿子多酚提取物及其制备方法和应用 Download PDFInfo
- Publication number
- CN115998779B CN115998779B CN202310078169.8A CN202310078169A CN115998779B CN 115998779 B CN115998779 B CN 115998779B CN 202310078169 A CN202310078169 A CN 202310078169A CN 115998779 B CN115998779 B CN 115998779B
- Authority
- CN
- China
- Prior art keywords
- sargassum pallidum
- polyphenol
- polyphenol extract
- sargassum
- pallidum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 114
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims abstract description 113
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 238000000605 extraction Methods 0.000 title description 5
- 235000017519 Artemisia princeps Nutrition 0.000 title description 4
- 244000065027 Artemisia princeps Species 0.000 title description 4
- 241000220690 Sargassum pallidum Species 0.000 claims abstract description 94
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 19
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 19
- 241000199919 Phaeophyceae Species 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 229940088598 enzyme Drugs 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- 229920000615 alginic acid Polymers 0.000 claims description 15
- 235000010443 alginic acid Nutrition 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 102000004317 Lyases Human genes 0.000 claims description 12
- 108090000856 Lyases Proteins 0.000 claims description 12
- 108010059892 Cellulase Proteins 0.000 claims description 10
- 229940106157 cellulase Drugs 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 15
- 230000002757 inflammatory effect Effects 0.000 abstract description 12
- 102000003814 Interleukin-10 Human genes 0.000 abstract description 10
- 108090000174 Interleukin-10 Proteins 0.000 abstract description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 9
- 206010012735 Diarrhoea Diseases 0.000 abstract description 9
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 abstract description 9
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract description 9
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 9
- 208000035861 hematochezia Diseases 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 230000000968 intestinal effect Effects 0.000 abstract description 6
- 230000004580 weight loss Effects 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 208000016261 weight loss Diseases 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 28
- 210000001072 colon Anatomy 0.000 description 21
- 238000011282 treatment Methods 0.000 description 13
- 235000001405 Artemisia annua Nutrition 0.000 description 12
- 240000000011 Artemisia annua Species 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000001913 cellulose Substances 0.000 description 8
- 229920002678 cellulose Polymers 0.000 description 8
- 229920003045 dextran sodium sulfate Polymers 0.000 description 8
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229960001553 phloroglucinol Drugs 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 229920001339 phlorotannin Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- LWRSYTXEQUUTKW-UHFFFAOYSA-N 2,4-dimethoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(OC)=C1 LWRSYTXEQUUTKW-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- -1 caraway polyphenol Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 229920002138 Eckol Polymers 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 229930189724 Fucophlorethol Natural products 0.000 description 1
- 229920000966 Fucophlorethol A Polymers 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 241000264279 Sargassum fusiforme Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
评分 | 体重下降(%) | 大便出血 | 大便性状 |
0 | 0 | 隐血阴性 | 正常 |
1 | 1-5% | 隐血阳性 | 松散成型 |
2 | 5-10% | 隐血强阳性 | 松散 |
3 | 10-15% | 肉眼可见轻微出血 | 中度腹泻 |
4 | >15% | 肉眼可见大量出血 | 重度腹泻 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310078169.8A CN115998779B (zh) | 2023-01-16 | 2023-01-16 | 一种海蒿子多酚提取物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310078169.8A CN115998779B (zh) | 2023-01-16 | 2023-01-16 | 一种海蒿子多酚提取物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115998779A CN115998779A (zh) | 2023-04-25 |
CN115998779B true CN115998779B (zh) | 2024-04-12 |
Family
ID=86037286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310078169.8A Active CN115998779B (zh) | 2023-01-16 | 2023-01-16 | 一种海蒿子多酚提取物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115998779B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110295209A (zh) * | 2019-07-08 | 2019-10-01 | 山东德图农业科技有限公司 | 一种酶解马尾藻提取褐藻胶寡糖的工艺方法 |
CN111154701A (zh) * | 2020-02-24 | 2020-05-15 | 荣成市泓派海洋生物科技有限公司 | 一种产褐藻胶裂解酶和纤维素酶的菌株及其在发酵海带中的应用 |
KR20210005526A (ko) * | 2019-07-03 | 2021-01-14 | 주식회사 만나스 | 플로로탄닌을 유효성분으로 포함하는 장기능 개선용 조성물 및 제품 |
CN114366760A (zh) * | 2021-12-30 | 2022-04-19 | 江苏海洋大学 | 海蒿子多酚在制备治疗糖尿病药物中的应用及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109561711B (zh) * | 2017-04-30 | 2023-08-22 | 特里同阿盖亚创新公司 | 治疗消化道病症的方法 |
-
2023
- 2023-01-16 CN CN202310078169.8A patent/CN115998779B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210005526A (ko) * | 2019-07-03 | 2021-01-14 | 주식회사 만나스 | 플로로탄닌을 유효성분으로 포함하는 장기능 개선용 조성물 및 제품 |
CN110295209A (zh) * | 2019-07-08 | 2019-10-01 | 山东德图农业科技有限公司 | 一种酶解马尾藻提取褐藻胶寡糖的工艺方法 |
CN111154701A (zh) * | 2020-02-24 | 2020-05-15 | 荣成市泓派海洋生物科技有限公司 | 一种产褐藻胶裂解酶和纤维素酶的菌株及其在发酵海带中的应用 |
CN114366760A (zh) * | 2021-12-30 | 2022-04-19 | 江苏海洋大学 | 海蒿子多酚在制备治疗糖尿病药物中的应用及其制备方法 |
Non-Patent Citations (3)
Title |
---|
海藻多酚功能性作用机制及其应用研究;彭雍博;罗宣;汪秋宽;宋悦凡;任丹丹;丛海花;;大连海洋大学学报;第32卷(第04期);485-490 * |
褐藻胶裂解酶的研究进展;罗丹丹;薛永常;;生物学杂志;第33卷(第06期);95-98 * |
超声辅助乙醇提取海带多酚工艺优化及抗氧化活性;苏艳玲;张谨华;;中国调味品;第45卷(第06期);174-180 * |
Also Published As
Publication number | Publication date |
---|---|
CN115998779A (zh) | 2023-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110559403A (zh) | 具有防治高尿酸血症的中药组合物及其制备方法与应用 | |
CN115998779B (zh) | 一种海蒿子多酚提取物及其制备方法和应用 | |
CN114989258B (zh) | 植物提取组合物在制备治疗便秘、减肥产品上的应用 | |
CN114748518B (zh) | 含有咖啡酸酯和灯盏花素的抗肠癌的口服制剂及其制备方法 | |
CN111714519A (zh) | 海蟑螂有机溶剂提取物的应用及组合物 | |
AU2019100737A4 (en) | Anti-Helicobacter Pylori Traditional Chinese Medicine composition and applications | |
JP7157253B2 (ja) | 潤腸便通の漢方薬組成物、その調製方法及びその用途 | |
CN102145076B (zh) | 地黄及其提取物的制药用途 | |
CN105497167A (zh) | 猫爪草在制备治疗和/或预防溃疡性结肠炎药物方面的新用途 | |
CN107158084B (zh) | 治疗桥本氏甲状腺炎的药物组合物及其制备方法和用途 | |
KR101647506B1 (ko) | 황련 추출물의 독성 저감화 방법, 이로부터 제조된 독성이 저감화된 생약추출물, 및 그 생약추출물을 함유하는 호흡기 질환 예방 또는 치료용 조성물 | |
CN101804128B (zh) | 一种治疗炎症性肠病的药物组合物及该组合物在制备治疗炎症性肠病药物中的用途 | |
CN115463164B (zh) | 麻黄根乙酸乙酯部位的制备方法及其药物和用途 | |
CN104857070A (zh) | 一种抗肠道炎性损伤的药物组合物及其制备方法和用途 | |
CN117683150B (zh) | 一种沙棘果皮多糖及其制备方法和用途 | |
Min et al. | Effectiveness of Fuling (Poria) and its extracts against spleen deficiency in rats via tonifying spleen | |
CN114601891B (zh) | 一种具有抗溃疡性结肠炎功效的组合物及其制备方法 | |
CN114588193B (zh) | 一种含山竹活性物的组合物及其制备方法和用途 | |
CN113713016B (zh) | 代代花在制备改善脂肪肝药物中的应用 | |
CN116139258B (zh) | 刺梨sod在制备用于预防或治疗肠道疾病药物中的用途 | |
CN114558026B (zh) | 半枝莲多糖在制备治疗炎症性肠病的药物中的应用 | |
CN113057326B (zh) | 一种含猴头菇的组合物的制备方法及其应用 | |
JP2006117566A (ja) | 糖代謝改善剤 | |
EP3964222A1 (en) | Pharmaceutical composition comprising mixture extract of coptis deltoidea and schizonepeta tenuifolia as active ingredient for prevention or treatment of inflammatory bowel disease | |
CN108403746B (zh) | 岩藻多糖组合制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240410 Address after: Room 2003, Unit 2, Building 11, No. 29 Haier Road, Laoshan District, Qingdao City, Shandong Province, 266101 Applicant after: Qingdao Keda Future Biotechnology Co.,Ltd. Country or region after: China Applicant after: QINGDAO University OF SCIENCE AND TECHNOLOGY Address before: 266061 Songling Road, Laoshan District, Qingdao, Shandong Province, No. 99 Applicant before: QINGDAO University OF SCIENCE AND TECHNOLOGY Country or region before: China |
|
TA01 | Transfer of patent application right |